Chembio Diagnostics, Inc. (CEMI)
CEMI Price and Sentiment
CEMI Latest news
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript
2021-11-08 04:40Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript
Chembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021
2021-10-21 16:51HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021.
Chembio Announces EUA Submission for DPP Respiratory Antigen Panel
2021-09-22 08:00Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2 Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2
Investing in Penny Stocks in September? 3 Strategies to Know
2021-08-29 18:15Trading penny stocks in September? You need to know these 3 things The post Investing in Penny Stocks in September?
Hot Penny Stocks to Buy This Month? 3 to Watch Now
2021-08-29 11:30Which penny stocks are on your watchlist for next month? The post Hot Penny Stocks to Buy This Month?
Why Chembio Diagnostics Shares Are Trading Higher Today
2021-08-27 15:43Chembio Diagnostics Inc (NASDAQ: CEMI) is trading higher Friday after the company announced its launch of commercial distribution of SCOV-2 Ag Detect Rapid Test, a third party COVID-19 antigen assay. Chembio Diagnostics said product inventory is on-hand and immediately available for shipment to customers across the United States.
Chembio Starts Distribution of Third-Party COVID-19 Antigen Assay
2021-08-27 08:34Chembio Diagnostics Inc (NASDAQ: CEMI) has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test. Product inventory is on-hand and immediately available for shipment to Chembio customers across the U.S.
Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay
2021-08-27 08:00HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to Chembio customers across the United States.
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript
2021-08-07 17:02Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript
Implied Volatility Surging for Chembio Diagnostics (CEMI) Stock Options
2021-08-06 12:16Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.